Clopidogrel Resistance Is Associated With Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial Infarction
By S. Matetzky, B. Shenkman, V. Guetta, M. Shechter, R. Beinart, I. Goldenberg, I. Novikov, H. Pres, N. Savion, D. Varon and 1 more. Circulation, 2004
1,415 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/27281bef5263f21cf8558938f034f681dba1610d
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Surgery
Citations in the corpus
- Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. (2005, background): “The emerging question about possible clopidogrel resistance requires more investigation.(225,226)”
- The management of antithrombotic agents for patients undergoing GI endoscopy. (2016, background): “This altered metabolism results in variable antiplatelet effects and adverse cardiac events,(43) including stent thrombosis(44) and post–percutaneous coronary intervention ischemic events.(45) The minimum duration of discontinuation of clopidogrel that allows for restoration of normal platelet aggre”
- Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. (2009, background): “Both high platelet-activity levels and clopidogrel nonresponse have been associated with increased risk of adverse events following stent implantation.(6,7) Thus, prior studies suggest the hypothesis that an attenuation of the antiplatelet effects of clopidogrel by omeprazole could lead to adverse c”
- Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. (2006, neutral): “CYP2C19*2 681GA (rs4244285) 681A: cryptic splicing site None GG (20); GA ( 8 ); AA (0) G (85.7); A (14.3) CYP3A5*3 6986GA (rs776746) 6986G: alternative splicing None GG (27); GA (1); AA (0) G (98.2); A (1.8) CYP2B6*5 1459CT (rs3211371) Amino acid substitution; Arg487Cys Decreased CC (23); CT (5); TT”
- Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. (2006, neutral): “Minor bleeding events 12 (29) 17 (44) 19 (51) 22 (48) 12 (32) Venipuncture site bruise 1 (2) 0 (0) 1 (3) 2 (4) 4 (11) Epistaxis 1 (2) 4 (10) 4 (11) 8 (17) 2 (5) Contusion 5 (12) 9 (23) 9 (24) 12 (26) 8 (22) Red blood cells in urine 3 (7) 0 (0) 4 (11) 0 (0) 1 (3) Dyspnoea 4 (10) 4 (10) 6 (16) 9 (20) ”
- Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. (2010, result): “8%-100%), reaction units using the VerifyNow P2Y12 test (1, 146; 2, 146-198; 3, 198-235; 4, 235-276; 5, 276-413), % surface coverageusingthe IMPACT-Rtest (1, 3.”
- Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. (2008, background): “ADP-induced platelet reactivity on light transmittance aggregometry (LTA) has been associated with adverse outcomes after percutaneous coronary intervention (PCI).(8) –14 Case–control”